Dr. Roychowdhury is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2050 Kenny Rd
Tower 8th Floor
Columbus, OH 43221Phone+1 614-685-5842Fax+1 614-293-9469- Is this information wrong?
Summary
- Dr. Sameek Roychowdhury is an oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. He received his medical degree from Ohio State University College of Medicine and has been in practice 11 years. He is experienced in hematologic oncology.
Education & Training
University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 2008 - 2011- University of Michigan Health SystemResidency, Internal Medicine, 2006 - 2008
Ohio State University College of MedicineClass of 2006
Certifications & Licensure
OH State Medical License 2012 - 2026
MI State Medical License 2006 - 2013- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing Start of enrollment: 2013 Nov 04
- Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Start of enrollment: 2015 Feb 24
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Start of enrollment: 2020 Jan 16
Publications & Presentations
PubMed
- 3 citationsThe future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.Samantha M Ruff, Sameek Roychowdhury, Timothy M Pawlik> ;Expert Opinion on Pharmacotherapy. 2023 May 1
- 2 citationsPan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations.Hoskins, E., Samorodnitsky, E., Wing, M., Reeser, J., Hopkins, J., Murugesan, K., Kuang, Z., Vella, R., Stein, L., Risch, Z., Yu, L., Adebola, S., Paruchuri, A., Carpt...> ;JCO Precision Oncology. 2023 Jan 1
- 5 citationsPan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.K Murugesan, A Necchi, T C Burn, O Gjoerup, R Greenstein, M Krook, J A López, M Montesion, H Nimeiri, A R Parikh, S Roychowdhury, S Schwemmers, I M Silverman, A Vogel> ;ESMO Open. 2022 Dec 1
- Join now to see all
Press Mentions
Blood Test for Cancer Now Available, but Is It Ready for Prime Time?August 16th, 2022- 'Autopsy Trial' Allows Researchers to Explore How Cancer Patients' Disease Overcomes TreatmentSeptember 29th, 2021
Fibroblast Growth Factor Receptors in Cancer: Genetic Alterations, Diagnostics, Therapeutic Targets and Mechanisms of ResistanceDecember 3rd, 2020- Join now to see all
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
Ohio State University Wexner Medical CenterColumbus, Ohio
The OSUCCC - JamesColumbus, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
